Biogen (NASDAQ: BIIB)
Biogen Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Biogen Company Info
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
News & Analysis
Biogen Exceeds EPS Estimate, Revenue Declines
Biogen reported mixed third-quarter results, with EPS beating expectations despite a decline in total revenue.
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?
Biogen stock has slipped 18% so far this year.
Why Biogen Stock Leaped Nearly 5% Higher Today
The company came out swinging with its first set of quarterly earnings for this year.
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
Getting its Alzheimer's medicine approved in the European Union could be big.
These Could Be the Biggest Nasdaq-100 Winners in 2024, According to Wall Street
Nice gains could be on the way for three stocks if analysts are right.
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
The real competitive battle is about to begin, and it will last a long time.
3 Struggling Stocks Investors Shouldn't Buy on the Dip
These stocks have been brutal investments to own in recent years -- and investors shouldn't expect things to get better.
Is Biogen Stock a Buy Now?
It has been one of the most talked about biotechs in recent years, but that's not enough to make its shares a buy.
Valuation
Podcast Episodes
3 Biotech Companies Analyzed
We examine three biotech companies' past performances and future outlooks.
Is There Still Room to Profit From Biogen?
The biotech popped 30% after the extremely unusual revival of an Alzheimer's treatment that had looked like a failure at first.
INDUSTRY FOCUS // Healthcare // 05-11-2016
GlaxoSmithKline takes on Pfizer and Biogen battles Celgene in this healthcare edition of Industry Focus.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.